For an adult patient with metastatic hormone‑sensitive prostate cancer in 2026, is oral relugolix (Orgovyx) or injectable leuprolide (Lupron) the preferred first‑line androgen‑deprivation therapy?

Orgovyx (Relugolix) is the Better Option for Metastatic Prostate Cancer in 2026

For adult patients with metastatic hormone-sensitive prostate cancer in 2026, oral relugolix (Orgovyx) is superior to injectable leuprolide (Lupron) and should be the preferred first-line androgen-deprivation therapy. This recommendation is based on the HERO trial demonstrating superiority in testosterone suppression, a 54% reduction in major cardiovascular events, and faster testosterone recovery 1.

Key Evidence Supporting Relugolix

Superior Efficacy

The phase 3 HERO trial directly compared relugolix to leuprolide and demonstrated:

• 96.7% of patients maintained castrate testosterone levels (<50 ng/dL) through 48 weeks with relugolix versus 88.8% with leuprolide (difference of 7.9 percentage points, P<0.001 for superiority) 1
• 56% of patients achieved castrate levels by day 4 with relugolix versus 0% with leuprolide 1
• Relugolix met both non-inferiority and superiority endpoints 1

Critical Cardiovascular Safety Advantage

The incidence of major adverse cardiovascular events was 2.9% with relugolix versus 6.2% with leuprolide (hazard ratio 0.46,95% CI 0.24-0.88), representing a 54% risk reduction 1. This is particularly crucial since:

• Prostate cancer patients often have cardiovascular comorbidities
• Traditional ADT is associated with cardiovascular risks
• This benefit makes relugolix especially valuable for patients with pre-existing cardiac disease 2, 3

Rapid Testosterone Recovery

In the testosterone recovery subgroup (n=184), mean testosterone levels 90 days after treatment discontinuation were:

• 288.4 ng/dL with relugolix versus 58.6 ng/dL with leuprolide 1
• This translates to 52% recovery with relugolix versus 16% with leuprolide 2
• Clinically relevant for intermittent ADT strategies or treatment cessation scenarios

No Testosterone Flare

Unlike leuprolide (an LHRH agonist), relugolix is a GnRH antagonist that:

• Directly suppresses LH and FSH without initial testosterone surge 4
• Avoids transient clinical symptom exacerbation
• Eliminates risk of tumor flare or spinal cord compression worsening 5

Practical Clinical Considerations

FDA Approval Status

Relugolix is FDA-approved for advanced prostate cancer with the following dosing 6:

• Loading dose: 360 mg on day 1
• Maintenance: 120 mg orally once daily
• Can be taken with or without food
• Tablets must be swallowed whole (not crushed or chewed)

Drug Interactions Requiring Attention

P-glycoprotein (P-gp) inhibitors: Avoid co-administration; if unavoidable, take Orgovyx first, separate dosing by at least 6 hours, and monitor more frequently 6

Combined P-gp and strong CYP3A inducers: Avoid co-administration; if unavoidable, increase Orgovyx dose to 240 mg once daily 6

Real-World Performance

Real-world data confirms trial results 2, 3:

• 98% of patients achieve castrate testosterone levels

• High patient adherence to oral regimen
• Safety profile consistent with clinical trials
• Cost-effectiveness demonstrated despite higher drug acquisition cost

Quality of Life

The EORTC QLQ-C30 and QLQ-PR25 assessments showed:

• No statistically significant differences in HRQOL between relugolix and leuprolide during treatment 7
• During testosterone recovery, hormonal treatment-related symptom scores were lower with relugolix, suggesting reduced burden of hormone-related symptoms 7

When Relugolix is Especially Preferred

Absolute priority situations:

• Patients with cardiovascular disease or risk factors (54% CV event reduction)
• Impending spinal cord compression or neurologic compromise (no flare risk, rapid suppression) 5
• Patients requiring rapid testosterone suppression
• Patients preferring oral over injectable therapy
• Intermittent ADT candidates (faster testosterone recovery)

Guideline Context

The 2025 NCCN Guidelines for Prostate Cancer 8 and 2023 ESMO Guidelines 9 both recognize relugolix as an appropriate ADT option. The ESMO Guidelines specifically note relugolix achieved "non-inferior and superior castration rate" with "significantly lower risk of major CV events (HR 0.46,95% CI 0.24-0.88)" and assign it an ESMO-MCBS score of 4 9.

Common Pitfalls to Avoid

• Do not assume equivalent efficacy: Relugolix demonstrated statistical superiority, not just non-inferiority
• Do not overlook cardiovascular history: The CV benefit is substantial and clinically meaningful
• Do not forget drug interactions: Screen for P-gp inhibitors and CYP3A inducers
• Do not crush tablets: Must be swallowed whole for proper absorption 6
• Monitor for hypersensitivity: Can cause angioedema; withhold for symptoms, discontinue for severe reactions 6

Warnings and Precautions

• QT/QTc interval prolongation: All ADT may prolong QT interval 6
• Embryo-fetal toxicity: Males with female partners of reproductive potential must use effective contraception 6
• Most common adverse reactions (≥10%): Hot flush, glucose increased, triglycerides increased, musculoskeletal pain, hemoglobin decreased, ALT increased, fatigue, AST increased, constipation, diarrhea 6